CP-526,555 (varenicline)
Sponsors
Pfizer
Conditions
Smoking Cessation
Phase 2
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
CompletedNCT00139750
Start: 2004-12-31End: 2006-02-28Target: 600Updated: 2007-06-04
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
CompletedNCT00150228
Start: 2001-12-31End: 2002-09-30Target: 300Updated: 2007-06-04
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
CompletedNCT00150254
Start: 2001-09-30End: 2002-10-31Target: 625Updated: 2007-06-04
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
CompletedNCT00150241
Start: 2000-02-29End: 2002-01-31Target: 625Updated: 2015-10-19